Trial reportAddictive behaviors2013
Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial.
Trial report in Addictive behaviors, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025Pooled it
- N-acetylcysteine as a treatment for substance use cravings: A meta-analysis.Addiction biology · 2024Pooled it
- Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019Pooled it
- Longitudinal craving profiles in cannabis use disorder: A latent class growth analysis of the achieving cannabis cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) (CTN-0053) trial.Drug and alcohol dependence · 2026Trial
- Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence.Addictive behaviors · 2015Trial
- Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents.The American journal of drug and alcohol abuse · 2014Trial
- An evaluation of N-acetylcysteine in a sequential oxycodone and cocaine rat self-administration model.Experimental and clinical psychopharmacology · 2026Article
- N-acetylcysteine as a treatment for substance use cravings: A meta-analysis.medRxiv : the preprint server for health sciences · 2024Article
- N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research.Pharmacological reports : PR · 2021Review
- Effectiveness of N-acetylcysteine in Treating Clinical Symptoms of Substance Abuse and Dependence: A Meta-analysis of Randomized Controlled Trials.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Article
- Use of N-Acetylcysteine in Psychiatric Conditions among Children and Adolescents: A Scoping Review.Cureus · 2017Article
- Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse.The international journal of neuropsychopharmacology · 2017Review
- Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.CNS & neurological disorders drug targets · 2015Review
- The current status of medical marijuana in the United States.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2014Review
- Review
- Emerging issues for our nation's health: the intersection of marijuana use and cardiometabolic disease risk.Journal of addictive diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Marijuana is the most widely used illicit substance among youths and recent epidemiological data indicate that rates of marijuana use are on the rise. The purpose of this study was to examine marijuana craving trajectories among adolescents in an eight-week, placebo-controlled pharmacotherapy trial targeting marijuana cessation. All participants received contingency management and cessation counseling, and were randomized to either N-acetylcysteine (1200mg NAC twice daily; n=45) or placebo (n=44). Craving for marijuana was measured using the short-form of the Marijuana Craving Questionnaire (MCQ). Results demonstrated a significant decrease in MCQ scores over time for the total sample, but no significant differential change in scores between the NAC and placebo groups. This lack of significant difference is in the setting of NAC participants submitting significantly more negative urine cannabinoid tests as compared to placebo participants. This suggests that cessation effects associated with NAC may be mediated by effects other than marijuana craving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.